(MENAFN- Asia Times) Indonesia reported a record 2,069 coronavirus deaths in 24 hours Tuesday as the Southeast Asian nation faces its deadliest Covid-19 surge since the pandemic began.
Tuesday's grim tally was nearly 600 deaths higher than the previous day and topped last week's daily record 1,566 deaths, the health ministry said.
New infections also shot up to just over 45,000, from about 28,000 on Monday.
The eye-watering data comes after Indonesia this week loosened virus curbs by allowing small shops, streetside restaurants and some shopping malls to reopen after a three-week partial lockdown.
But health experts warned it could trigger a fresh wave of cases, as the highly infectious Delta variant tears across the vast archipelago, which has overtaken India and Brazil to become the global pandemic epicenter.
Shopping malls and mosques in less affected parts of the Muslim-majority nation also had the green light to open their doors from Monday, to limited crowds and with shorter hours.
Offices were still under shutdown orders.
Indonesia, the world's fourth most populous nation where tens of millions live hand to mouth, has avoided strict lockdowns seen in some other countries.
But the government has been widely criticized for its handling of the pandemic and policies that critics say prioritized Southeast Asia's largest economy over public health.
President Joko Widodo has pointed to falling daily infection and hospital occupancy rates, including in the hard-hit capital Jakarta, as justification for the easing.
But the Delta variant has been detected in about a dozen regions outside Jakarta, densely populated Java and Bali, where infections have also soared in recent weeks.
Indonesia's vaccination levels remain well below the government's one-million day target for July and less than 7% of its 270 million people have been fully inoculated with two jabs.
The country has reported a total of more than 3.2 million cases and 86,835 virus deaths, but those official figures are widely believed to be a severe undercount due to low testing and tracing rates.
Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.